#regulatory-strategy

#regulatory-strategy

The venture capital industry has long operated on a transactional model: evaluate the science, assess the team, write the check, and monitor progress through quarterly board meetings. This approach may work for software startups, but it fundamentally misaligns with biotechnology development realities. The path from laboratory breakthrough to FDA-approved therapy involves navigating regulatory mazes, recruiting specialized talent, and building relationships across interconnected scientific communities-challenges that capital alone cannot solve.